Tasly Pharmaceuticals and Mauna Kea Technologies Announce Joint Venture and Licensing Agreements
Mauna Kea to form Joint Venture (JV) with Tasly to develop, manufacture and commercialize Cellvizio for the Chinese market. JV also to acquire exclusive worldwide rights to develop and commercialize Cellvizio in the fields of Neurology and Neurosurgery
Subject to transferring IP assets and contributing licenses to the JV, Mauna Kea to receive 44% equity interest in the Joint Venture, cash payments totaling $10 million, and Cellvizio purchasing commitments for 5 years
Agreement accelerates Mauna Kea’s previously announced strategic repositioning
Mauna Kea Technologies and Tasly Pharmaceuticals today announced the execution of an agreement to form a Joint Venture (JV).
Under terms of the agreement, Tasly and Mauna Kea will form a Joint Venture that will (i) commercialize selected Cellvizio indications in China, (ii) develop and commercialize Cellvizio globally in the fields of Neurology and Neurosurgery, and (iii) manufacture Cellvizio units for the Chinese market. The JV will utilize both existing distribution partners and its own network of China-based marketing professionals to accelerate market adoption.
In exchange for contributing licenses and other intellectual property to the JV, Mauna Kea will receive cash payments totaling $10 million, a 44.1% equity interest in the JV, and a 5-year commitment to purchase minimum quantities of Cellvizio systems and probes. Mauna Kea’s equity holdings are net of shares issued to Cenponts Tech Limited in consideration for strategic advisory services provided in connection to the transaction. The Joint Venture will be majority owned and funded by Tasly and jointly managed by Tasly and Mauna Kea.
The Joint Venture will be in an immediate position to leverage Mauna Kea’s position as global leader in probe and needle-based confocal laser endomicroscopy, with its FDA clearance for neurosurgery applications, its broad regulatory clearances in the Chinese market as well as its significant installed based in leading hospitals in China.
Sacha Loiseau, Ph.D., founder and Chairman of Mauna Kea Technologies, stated: “We are delighted to partner with Tasly Pharmaceuticals, a life sciences leader in Asia-Pacific with a global presence. This transaction both expands the addressable market for Cellvizio and increases Mauna Kea’s capacity to invest further in product and clinical development, including molecular imaging and artificial intelligence. This announcement builds on the strategic repositioning we announced in December 2021 and our emphasis on forming capital-efficient partnerships that leverage the commercial reach of global biopharma and medtech firms while increasing patient access to Cellvizio.”
Kaijing Yan, Chairman of Tasly Pharmaceuticals Group, commented: “The field of biomedical engineering is an important part of Tasly Pharmaceuticals’ second growth curve strategy. The cooperation with Mauna Kea Technologies will enable us to quickly access large markets in China addressed by the multiple clinical applications of Confocal Laser Endomicroscopy. The recent advances in molecular imaging with Cellvizio are also of great interest to us since Tasly Pharmaceuticals could assist the Joint Venture in developing new combinations of Cellvizio with novel molecular markers, aligned with our vision of providing integrated solutions from diagnosis to treatment. We very much look forward to a fruitful and rich collaboration with Mauna Kea Technologies.”
Cenponts Tech Limited and McDermott Will & Emery advised Mauna Kea Technologies on the transaction.